Sufentanil NanoTab PCA System: Phase III started

AcelRx began a double-blind, placebo-controlled, U.S. Phase III trial to evaluate 15 µg sublingual Sufentanil NanoTabs given every 20 minutes via Sufentanil NanoTab PCA System for 48-72 hours in abou...